180 Wealth Advisors LLC Buys New Holdings in Celgene Co. (CELG)

180 Wealth Advisors LLC bought a new stake in shares of Celgene Co. (NASDAQ:CELG) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,904 shares of the biopharmaceutical company’s stock, valued at approximately $303,000.

Other hedge funds also recently bought and sold shares of the company. Arcadia Investment Management Corp MI grew its holdings in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares in the last quarter. Robecosam AG purchased a new position in shares of Celgene during the third quarter worth about $114,000. Guidant Wealth Advisors purchased a new position in shares of Celgene during the third quarter worth about $119,000. American Beacon Advisors Inc. purchased a new position in shares of Celgene during the fourth quarter worth about $120,000. Finally, Capital Bank & Trust Co grew its holdings in shares of Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares in the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

Shares of CELG stock opened at $86.95 on Friday. The company has a quick ratio of 4.80, a current ratio of 4.99 and a debt-to-equity ratio of 2.29. Celgene Co. has a fifty-two week low of $84.25 and a fifty-two week high of $147.17. The company has a market capitalization of $68,049.33, a price-to-earnings ratio of 12.71, a P/E/G ratio of 0.61 and a beta of 1.49.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter in the previous year, the company posted $1.61 earnings per share. The business’s revenue was up 16.9% on a year-over-year basis. equities analysts predict that Celgene Co. will post 7.66 EPS for the current year.

Celgene declared that its Board of Directors has approved a share repurchase plan on Wednesday, February 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Several research analysts have recently commented on the company. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price objective for the company in a report on Thursday, January 25th. Mizuho set a $128.00 price objective on Celgene and gave the stock a “buy” rating in a report on Tuesday, December 26th. BTIG Research reissued a “hold” rating on shares of Celgene in a report on Tuesday, January 23rd. BidaskClub raised Celgene from a “sell” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, Citigroup reissued a “hold” rating on shares of Celgene in a report on Friday, December 22nd. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $127.68.

In related news, insider Mark J. Alles acquired 3,260 shares of the stock in a transaction on Thursday, February 8th. The stock was purchased at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the transaction, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $94.83, for a total value of $877,177.50. Following the completion of the sale, the director now owns 94,801 shares of the company’s stock, valued at approximately $8,989,978.83. The disclosure for this sale can be found here. Insiders sold 41,120 shares of company stock valued at $3,879,509 in the last quarter. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3337100/180-wealth-advisors-llc-buys-new-holdings-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

SmileyCoin Reaches Market Capitalization of $1.87 Million
SmileyCoin Reaches Market Capitalization of $1.87 Million
DeltaCredits Market Capitalization Reaches $0.00
DeltaCredits Market Capitalization Reaches $0.00
Reviewing Piedmont Office Realty Trust  & Sampo Group
Reviewing Piedmont Office Realty Trust & Sampo Group
Havven  Price Up 28% Over Last 7 Days
Havven Price Up 28% Over Last 7 Days
Head to Head Survey: Roper Technologies  & Mesa Laboratories
Head to Head Survey: Roper Technologies & Mesa Laboratories
Comparing PCM  & The Competition
Comparing PCM & The Competition


© 2006-2018 Ticker Report. Google+.